Amylyx’s ALS Drug Lacks ‘Confirmatory Evidence’ Needed To Support Approval On Single Study, FDA Says

 
• By Sue Sutter
Tree in tree
Amylyx's ALS drug is getting a second chance with an FDA advisory committee. • Source: Shutterstock

More from US FDA Performance Tracker

More from Regulatory Trackers